Cargando…
Ocrelizumab: A Review in Multiple Sclerosis
Ocrelizumab (Ocrevus(®)) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The efficacy of ocrelizumab in reducing relapse rates and disease...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862399/ https://www.ncbi.nlm.nih.gov/pubmed/35192158 http://dx.doi.org/10.1007/s40265-022-01672-9 |